Oumaima Aboubakr, Alessandro Moiraghi, Angela Elia, Arnault Tauziede-Espariat, Alexandre Roux, Arthur Leclerc, Martin Planet, Aziz Bedioui, Giorgia Antonia Simboli, Frédéric Dhermain, Eduardo Parraga, Chiara Benevello, Houssem Fathallah, Jun Muto, Fabrice Chrétien, Edouard Dezamis, Catherine Oppenheim, Pascale Varlet, Marc Zanello, Johan Pallud
OBJECTIVE: Glioblastoma, isocitrate dehydrogenase (IDH)-wildtype is the most aggressive glioma with poor outcomes. The authors explored survival rates and factors associated with long-term survival in patients harboring a glioblastoma, IDH-wildtype. METHODS: In an observational, retrospective, single-center study, the authors examined the medical records of 976 adults newly diagnosed with supratentorial glioblastomas, IDH-wildtype between January 2000 and January 2021...
August 30, 2024: Journal of Neurosurgery